Entity

Time filter

Source Type

Bundoora, Australia

Gagnon A.,Rio Tinto Alcan | Backhouse N.,Rio Tinto Alcan | Darmstadt H.,Rio Tinto Alcan | Ryan E.,Research Ave | And 2 more authors.
TMS Light Metals | Year: 2013

The question of treating high-impurity coke to enable use in anodes was examined. A mineralogical analysis of different cokes demonstrated that more than 99 % of the particles contained the expected concentrations of sulfur, nickel, and vanadium while a small number of particles contained inclusions of other impurities. A number of potential treatment options were identified and investigated, with thermal desulfurization being studied further. The initial sulfur concentration, residence time and calcination temperature had the highest influence. 45 % sulfur removal was achieved but with significant bulk density loss. Acceptable pilot anode quality was not achievable even with the fines fraction substituted with desulfurized material. Therefore while sulfur removal during calcining is possible, the resulting coke, even in the most promising scenario, is not suitable for anode manufacturing. At this time, an industrial process to remove sulfur and other impurities from petroleum coke is unlikely to be viable. Source


Sleebs B.E.,Walter and Eliza Hall Institute of Medical Research | Sleebs B.E.,Research Ave | Street I.P.,Walter and Eliza Hall Institute of Medical Research | Street I.P.,Research Ave | And 3 more authors.
Synthesis | Year: 2010

A potent LIMK1 inhibitor, BMS4, was synthesised in six steps starting from pyrazine-2-carboximidamide, offering a significant improvement over current methods available in the literature. © 2010 Georg Thieme Verlag Stuttgart · New York. Source


Sleebs B.E.,Walter and Eliza Hall Institute of Medical Research | Sleebs B.E.,Research Ave | Sleebs B.E.,University of Melbourne | Levit A.,Walter and Eliza Hall Institute of Medical Research | And 15 more authors.
MedChemComm | Year: 2011

A high throughput chemical screening campaign has led to the identification of 3-aminobenzo[b]thiophene-2-carboxamides as LIMK1 inhibitors. Evolution of bicyclic hits to the tricyclic 4-aminobenzothieno[3,2-d]pyrimidine, using a traditional medicinal chemistry SAR guided approach, resulted in a significant increase in potency. Further elaboration has seen the 7-phenyl-4- aminobenzothieno[3,2-d]pyrimidine emerge as a LIMK1 inhibitor lead candidate. © The Royal Society of Chemistry 2011. Source


Sleebs B.E.,Walter and Eliza Hall Institute of Medical Research | Sleebs B.E.,Research Ave | Sleebs B.E.,University of Melbourne | Ganame D.,Walter and Eliza Hall Institute of Medical Research | And 15 more authors.
MedChemComm | Year: 2011

7-Phenyl-4-aminobenzothieno[3,2-d]pyrimidines were previously reported to exhibit moderate LIMK1 inhibition. Further exploration of SAR around the 7-phenyl moiety has led to the development of a lead series with an increased potency for LIMK1. Evaluation of physicochemical and ADME properties, and off-target kinase screens has seen this novel series emerge as a promising platform for a set of tool compounds for evaluating LIMK as a therapeutic target. © The Royal Society of Chemistry 2011. Source


Sleebs B.E.,Walter and Eliza Hall Institute of Medical Research | Sleebs B.E.,Research Ave | Sleebs B.E.,University of Melbourne | Nikolakopoulos G.,Walter and Eliza Hall Institute of Medical Research | And 11 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2011

4-Aminobenzothieno[3,2-d]pyrimidines were previously identified in a high throughput screening campaign as LIMK1 inhibitors. Scaffold reversal led to the identification of a series of simple 5,6-substituted 4-aminothieno[2,3-d] pyrimidines with low micromolar inhibition of LIMK1. © 2011 Elsevier Ltd. All rights reserved. Source

Discover hidden collaborations